CA2096520A1 - Agent therapeutique pour les maladies cutanees ou corneennes - Google Patents

Agent therapeutique pour les maladies cutanees ou corneennes

Info

Publication number
CA2096520A1
CA2096520A1 CA2096520A CA2096520A CA2096520A1 CA 2096520 A1 CA2096520 A1 CA 2096520A1 CA 2096520 A CA2096520 A CA 2096520A CA 2096520 A CA2096520 A CA 2096520A CA 2096520 A1 CA2096520 A1 CA 2096520A1
Authority
CA
Canada
Prior art keywords
skin
cpb
agent
therapeutic agent
corneal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2096520A
Other languages
English (en)
Other versions
CA2096520C (fr
Inventor
Hiroshi Nakao
Takao Nagoya
Yushi Saino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2096520A1 publication Critical patent/CA2096520A1/fr
Application granted granted Critical
Publication of CA2096520C publication Critical patent/CA2096520C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Agent thérapeutique pour la peau ou contre les maladies cornéennes, contenant en tant qu'ingrédient actif du CPB-1 ou du CPB-1 recombinant, composés qui présentent un fort pouvoir de stimulation de la néoformation de granulations de fibroblastes, de multiplication des cellules endothéliales et épithéliales, etc., et de réduction de l'activité PKC. Dès lors que cet agent présente un mécanisme d'action différent de celui de l'agent classique, il peut être employé en combinaison avec l'agent classique pour en améliorer l'effet thérapeutique, et présente donc une utilité remarquable dans le traitement de toutes sortes d'affections cornéennes et de la peau, en particulier des plaies et du psoriasis.
CA002096520A 1990-11-20 1991-11-19 Agent therapeutique pour les maladies cutanees ou corneennes Expired - Fee Related CA2096520C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31464890 1990-11-20
JP314648/1990 1990-11-20
PCT/JP1991/001587 WO1992008475A1 (fr) 1990-11-20 1991-11-19 Agent therapeutique pour la peau ou contre les maladies corneennes

Publications (2)

Publication Number Publication Date
CA2096520A1 true CA2096520A1 (fr) 1992-05-21
CA2096520C CA2096520C (fr) 2000-12-19

Family

ID=18055860

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002096520A Expired - Fee Related CA2096520C (fr) 1990-11-20 1991-11-19 Agent therapeutique pour les maladies cutanees ou corneennes

Country Status (11)

Country Link
US (1) US5360789A (fr)
EP (1) EP0558751B1 (fr)
JP (1) JP3126733B2 (fr)
KR (1) KR100191192B1 (fr)
AT (1) ATE189393T1 (fr)
CA (1) CA2096520C (fr)
DE (1) DE69131964T2 (fr)
DK (1) DK0558751T3 (fr)
ES (1) ES2143467T3 (fr)
GR (1) GR3033157T3 (fr)
WO (1) WO1992008475A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203976A1 (en) * 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
EP1155689B1 (fr) 1993-07-19 2006-09-20 Angiotech Pharmaceuticals, Inc. Stents anti-angiogéniques et leurs procédés de préparation
US5698533A (en) * 1994-07-26 1997-12-16 Kang; Meng-Che Ophthalmic pharmaceutical composition
JPH0848634A (ja) * 1994-08-05 1996-02-20 Akio Okamoto 角膜治療剤
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
ATE470449T1 (de) 2000-08-10 2010-06-15 Santen Pharmaceutical Co Ltd Förderer der hautwundheilung
US20050222030A1 (en) * 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
US6962903B2 (en) * 2001-02-21 2005-11-08 Alavita, Inc. Modified annexin proteins and methods for preventing thrombosis
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
CN1267150C (zh) * 2001-02-26 2006-08-02 兴和株式会社 滴眼剂
AU2003903896A0 (en) * 2003-07-28 2003-08-07 Queensland University Of Technology Skin regeneration system
JP5792057B2 (ja) 2008-04-01 2015-10-07 モサメディックス・ビー．ブイ．ＭｏｓａＭｅｄｉｘ Ｂ．Ｖ． 創傷治癒における瘢痕形成を低減するための組成物および方法
CN117860765A (zh) * 2023-12-27 2024-04-12 广东工业大学 麦角甾醇在制备治疗和/或预防银屑病药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1265446A (fr) * 1985-09-30 1990-02-06 Masahiro Maki Substance anticoagulante, procede de preparation et anticoagulant comprenant ces substances actives
JPH0764878B2 (ja) * 1986-10-14 1995-07-12 興和株式会社 抗血液凝固物質及びその製法
US4937324A (en) * 1987-02-06 1990-06-26 Zymogenetics, Inc. Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity
JP2660514B2 (ja) * 1987-02-20 1997-10-08 興和株式会社 抗血液凝固作用を有するポリペプチド
JPH06799B2 (ja) * 1987-04-02 1994-01-05 帝人株式会社 起炎性フオスフオリパ−ゼａ▲下２▼阻害活性を有する蛋白
DE68923107T2 (de) * 1988-02-26 1996-01-18 Biogen Inc DNA-Sequenzen, rekombinante DNA-Moleküle und Verfahren zur Herstellung von Lipocortin III, IV, V, und VI.
US5179081A (en) * 1988-07-21 1993-01-12 Kowa Co., Ltd. Method of treatment using an anticoagulant polypeptide

Also Published As

Publication number Publication date
JP3126733B2 (ja) 2001-01-22
EP0558751B1 (fr) 2000-02-02
DE69131964T2 (de) 2000-05-18
WO1992008475A1 (fr) 1992-05-29
ES2143467T3 (es) 2000-05-16
ATE189393T1 (de) 2000-02-15
EP0558751A4 (en) 1994-07-13
CA2096520C (fr) 2000-12-19
DE69131964D1 (de) 2000-03-09
US5360789A (en) 1994-11-01
KR100191192B1 (ko) 1999-06-15
EP0558751A1 (fr) 1993-09-08
DK0558751T3 (da) 2000-05-08
KR930702019A (ko) 1993-09-08
GR3033157T3 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
CA2096520A1 (fr) Agent therapeutique pour les maladies cutanees ou corneennes
ATE188118T1 (de) Zusammenfassungen und ihren verwendung in der behandlung von neurologischen krankheiten
ES2161229T3 (es) Microesferas bioterapeuticas revestidas con celulas.
IT8520110A0 (it) Elettrodo, apparecchiatura e defibrillazione per l'impianto in corpi umani o animali.
IE790756L (en) Cerebral therapeutic agent
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
ATE97813T1 (de) Mittel zur kontrolle von thrombenbildungen.
DE69535081D1 (de) Verwendung von Prostaglandin A oder dessen Derivaten zur Behandlung von Psoriasis
CA2163118A1 (fr) Fractions d'acide aurintricarboxylique et analogues avec activite anti-angiogenique; methodes d'utilisation
RU93042331A (ru) Глазные капли
IT8920898A0 (it) Uso di sucralfato gel umido per il trattamento di ulcere del derma e come veicolo di farmaci ad attivita' topica.
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
CA2091134A1 (fr) Agent therapeutique contre les risques d'avortement
MY107235A (en) Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase.
ATE113209T1 (de) Verwendung von 5-amino-salicylsäure für die behandlung von hautkrankheiten.
AU1926188A (en) N-benzoyl-n'-2,5-dihalo-4-perfluoroalkoxyphenylureas, their preparation and use in the control of pests
AU1621788A (en) Pharmacologically active cholinergic compositions, and methods for making same and use thereof in treating disease
FR2694694B1 (fr) Composition active pour le traitement du psoriasis, notamment le psoriasis du cuir chevelu.
DE68905076D1 (de) Pharmazeutische zusammensetzung fuer die behandlung von hautwunden.
CA2027075A1 (fr) Muteine de hst-1 et sa production
ATE97812T1 (de) Therapeutische verwendung des isopropylesterderivates von monosialogangliosiden bei erkrankungen des nervensystems, begleitet von entzuendungen.
RU2003337C1 (ru) Ранозаживл ющее средство
CA2097878A1 (fr) Agent therapeutique pour la neutropenie
Blomgren et al. A Clinical Study of Trypure® or Varidase® on Minor Burns
RU93053031A (ru) Способ снижения активности клеток, способ подавления раковых клеток и фармацевтические препараты для снижения активности клеток, способ лечения

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed